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     Cannabinoids induce diverse responses on anxiolytic–like behaviors. Moreover some studies postulated 
that there is a close relationship between this system and serotonergic system upon cognitive process 
formation. Thus the aim of present study is investigation the possible role of 5-HT1 receptor on anxiolytic–
like behaviors induced by ACPA in the elevated plus maze task (EPM). In the present study rats weighting 
250–300g upon surgery bilateral guide cannulae were implanted to allow microinjection of ACPA (agonist 
CB1 receptor), CP94253 Hcl(agonist 5-HT1 receptor) alone and them interaction in the AcbSh. 
The data showed pretest AcbSh infusion of ACPA at doses of0.0002, 0.002, 0.02 and 0.2 μg/rat increased 
and decreased the percentage of open-arms time (%OAT) and percentage of Enclosed-arms time (%CAT), 
respectively as compared to control groups. Pretest AcbSh infusion ofCP94253 Hcl at doses of 5, 0.5 and 
0.05 ng/rat, did not alter anxiety-like behaviors. In addition intra-AcbSh microinjection of subthreshold dose 
of CP94253 Hcl did not alter ACPA-induced anxiolytic-like behaviors. Our data suggest that activation of 
AcbSh 5-HT1 receptor did not involve in ACPA-induced behaviors in the EPM task. 
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INTRODUCTION 
   Scientists have investigated a main role in the 
long history of cannabinoid and endocannabinoid 
research. These kinds of research has gained from 
the first important evaluation of the medicinal 
properties and chemical components of Cannabis 
sativa, the development of in vitro biological 
assays to study cannabinoids, the recognitionof the 
mechanism of action, the discovery of 
endocannabinoids and the assessment of their 
therapeutic suggestions[1]. 
Cannabinoid has been used for hundreds of years 
for both recreational and medicinal purpose. 
Cannabis has the ability to create euphoria, 
lethargy, confusion, depersonalization, altered time 
sense, impaired motor performance, memory 
defects, paranoia, depression, fear, anxiety and 
hallucinations [2]. When the endogenous 
cannabinoid system was appeared, research in the 
fields of pharmacology and therapeutic of 
cannabinoids has increased day after day [3]. There 
are three well-known cannabinoid receptors in 
humans and animals which are called the CB1, 
CB2 and CB3 receptors [4, 5]. The effects of 
cannabinoids are expressed by its receptors. 
Recently the information about serotonin's role in 
behavior has been recognized. The identification of 
drugs acting on the serotonergic system of brain 
that are applied for the remedy of depression, 
anxiety, appetite regulation, and post-traumatic 
stress disorders has greatly emphasized to pay 
careful attention on role of serotonin in processes 
dealing with emotional condition [6]. 
Serotonin receptor subtypes including the 5-HT1, 
5-HT2, 5-HT3, 5-HT4, 5-HT6, and 5-HT7 class of 
receptors are involved in anxiety, learning and 
memory [7, 8]. 5-HT1B receptors are distributed 
broadly in the CNS in serotonergic and 
 




nonserotonergic neurons; these receptors are 
predominantly translocate to axon terminals[9]. 
The dorsal (DRN) raphe nuclei (MRN) are two 
mainorigins of serotonergic projections to the 
forebrain. The DRN serotonergic projections are 
probablyassociated with cognitive and 
emotionactivity[10, 11]. The DRNand one of 
serotonergic ascending projection sites, that is, 
nucleus accumbens (NAcc)[12].  
The nucleus accumbens is divided into two 
regions: core and shell.5-HT synapses are plentiful 
and have a greater number of synaptic contacts in 
the NAc shell than in the core [13]. The aim of 
present study is to investigate the serotonergic 
system effect and interaction with cannabinoids on 
like-anxiety behaviors. 
 
MATERIALS AND METHODS 
     Male Wistar rats weighing 250–300 g upon 
surgery were housed in groups of five per cage 
under standard laboratory conditions, with a 12-h 
light/12-h dark cycle. Eight animals were used in 
each group of experiments. The experiments were 
carried out during the light phase of the cycle.  
Arachidonoylcyclopropamide (ACPA),agonist 
receptor 5-HT1(CP94253 Hcl) were dissolved in 
saline solution (0.9%) and Control animals 
received saline.  
An EPM, made of Plexiglas and consisting of two 
opposite open-arms (50×10 cm) surrounded by a 1 
cm high ledge, and two enclosed-arms (50×10×40 
cm) was used. The maze was set up 50 cm above 
the floor. The junction area of the four arms 
(central platform) measured 10×10 cm [14, 15]. 
Two unilateral guide-cannulae (through which an 
injection cannula could be inserted for drugs, 
saline, 5-7 days later) were stereotaxically 
implanted over the left and right AcbShell. Taking 
bregma as the reference point, the coordinates for 
the AcbShell were AP = +1.7mm, ML = ±0.8mm 
and DV =5.9mm, according to the atlas of Paxinos 
and Watson [16]. Five to seven days post surgery, 
rats received a bilateral infusion into the AcbSh 
using dental needles (27-gauge) introduced through 
guide cannulae. Then 0.3 μl/side of solution were 
injected into AcbSh, respectively.  
Statistical Analysis 
   The data were analyzed by one-way analysis of 
variance (ANOVA) for test and retest sessions 
and expressed as mean±S.E.M. Post hoc Tukey 
test was performed when significant F-values 
were obtained in the ANOVA. Values of P<0.05 
were considered statistically significant.  
Experimental Design 
Experiment 1  
   To examine whether the microinjection of drugs 
into the AcbSh involve in anxiety, the drugs were 
infused before EPM testing. In this experiment 4 
groups of animals received saline (0.3 µl/side), 
CP94253 (5-HT1 receptor agonist; 0.05, 0.5 and 5 
ng/rat). 
Experiment 2 
   To test the possible involvement of ACPA in 
anxiety, the drug was infused before EPM testing. 
In this experiment received ACPA (0.0002, 
0.002,0.02 and 0.2µg/rat) 5 min before testing.  
Experiment 3 
   Aiming to assess the possible interaction 
between 5-HT1 AcbSh receptors upon ACPA-
induced exploratory-like behaviors, drugs were 
administered before the EPM testing session. In 
this experiment 4 groups of animals received the 
subthreshold dose of CP94253 Hcl(0.05 ng/rat).In 
addition, all these animals received saline 
(0.3µl/side) and the subthreshold andeffective 





    Repeated measure and post hoc analysis 
showed that intra-AcbSh injection of CP94253 at 
applied doses did not alter %OAT[F(3,28)=2.355, 
P>0.05,fig.1; A], %CAT[F(3,28)=2.359, P>0.05, 
fig.1; B),%OAE (F(3,28)=2.053, P>0.05, fig.1; C), 
%CAE[F(3,28)=2.124, P>0.05, fig.1; D) on test day 
as compared to control group, indicating that the 
drug does not seem to alter anxiety-like behaviors. 
Experiment 2 
   Repeated measure and post hoc analysis showed 
that intra-AcbSh injection of ACPA at applied 
doses did not alter %OAE [F(4,35)=2.059, P>0.05, 
fig.2; panel 1C), %CAE [F(4,35)=2.230, P>0.05, 
fig.2; panel 1D] and increased 
%OAT[F(4,35)=4.217, P<0.01, fig.2;panel 1A), 
%CAT [F(4,35)=4.210, P<0.01, fig.2; panel 1B] on 
test day as compared to control group, indicating 
that the drug higher dose leave an effect on 
anxiolytic-like behaviors. 
 






Figure 1. The effects of pretest infusion intra-AcbSh 
CP942253 on anxiety-like behaviors. %Open-arms 
time (A); %Closed-arms time (B); %Open-arms entries 




   Two-way ANOVA and post hoc analysis 
showed that intra-AcbShell injection of the 
subthreshold dose CP94253 did not alter %OAT 
[F(4,70)=1.045, P>0.05,fig.2;panel 2A], %CAT 
[F(4,70)=1.043, P>0.05, fig.2; panel 2B], %OAE 
[F(4,70)=2.404), P>0.05, fig.2; panel 2C], %CAE 
[F(4,70)=1.452, P>0.05, fig.2; panel 2D] indicating 
that CP94253 did not alter ACPA-induced 
anxiolytic-like behaviors. 
Moreover data intra-group showed that did not 
alter %OAT [F(1,70)=0.292, P>0.05,fig.2;panel 
2A], %CAT [F(1,70)=0.293, P>0.05, fig.2; panel 
2B], %OAE [F(1,70)=0.380), P>0.05, fig.2; panel 
2C], %CAE [F(1,70)=0.788, P>0.05, fig.2; panel 
2D] while significantly  inter-group alter %OAT 
[F(4,70)=8.697, P<0.01,fig.2;panel 2A], %CAT 
[F(4,70)=8.680, P<0.01, fig.2; panel 2B], %OAE 
[F(4,70)=8.377), P<0.01, fig.2; panel 2C], %CAE 
[F(4,70)=5.516, P>0.05, fig.2; panel 2D]compared 
to own control group.  
  
DISCUSSION 
    Regarding the fact that animal models applied, 
concerning to the study of learning and memory, 
have a restricted capability to test the effect of 
drugs on anxiety and fear-related memory, the 
interpretation of such obtained data may often be 
misleading. In order to simultaneously assess the 
effects of drugs on anxiety, learning and memory 
as well, the elevated plus-maze (EPM) test-retest 
paradigm in rodents is used [17]. The use of EPM 
in testing anxiety is based on the natural tendency 
of animals to avoid the dangerous situation when 
they face height and open spaces [18]. 
Cannabinoids induce wide-ranging responses on 
anxiety- and fear-related behaviors. On the whole, 
low doses induce anxiolytic-like effects, while 
high doses often cause the opposite effects [19]. 
Some investigations have revealed that the CB1 
receptor antagonist SR141716A antagonized the 
effect of CB1 receptor. Thus the involvement of 
this subtype of cannabinoid receptor and its effect 
were revealed [20]. When cannabinoid receptor 
agonists, WIN 55212-2 and CP55940, 
systemically administered it increased the time 
mice spend on the open arms on EPM (i.e., elicit 
an anxiolytic response) only at low doses. In 
contrast, THC produces a dose-dependent 
reduction in time spent on open arms [21].  
 





Figure 2. The effects of pretest infusion intra-AcbSh of ACPA alone and CP94253 induced by ACPAonanxiety-like 
behaviors.*P<0.05, **P<0.01 and ***P<0.001 as compared control group. %Open-arms time (A); %Closed-arms time 
(B); %Open-arms entries (C); %Enclosed-arms entries (D). 
 
Furthermore, systemic administration of the CB1 
receptor antagonists SR141716 and AM251 
reduces the time spent on open arm. THC induces 
increased aversion to the open arms of the EPM in 
both rats and mice and anxiogenic agents too, 
produce the same kind of aversion [22]. Hence, in 
models predicative of anxiolytic-like activity, low 
doses of CB1 agonists are anxiolytic and high 
doses increase aversion and anxiety-related 
behaviors [23]. The present results also indicate 
that intra-AcbShinfusion of ACPA at doses 
of0.0002, 0.002, 0.02 and 0.2 μg/rat increased 
 




anxiolytic-like behaviors in EPM task as 
compared to control groups. There is no consent 
between the role of serotonin in anxiety 
behaviorwhether serotoninincreases ordecreases 
it[24]. These results express that it is suitableto 
make a decisionabout an “anxiogenic” or 
“anxiolytic” role for 5-HT we should pay 
attention toits site of action in the brain and/or the 
receptor subtype[25]. 
In the present study, Pretest AcbSh infusion of 
CP94253 Hcl at doses of 5, 0.5 and 0.05 ng/rat, 
did not alter anxiety-like behaviors. In addition 
intra-AcbSh microinjection of subthreshold dose 
of CP94253 Hcl did not alter ACPA-induced 
anxiolytic-like behaviors. The provided data 
express that activation of AcbSh 5-HT1 receptor 
did not involve in ACPA-induced behaviors in the 
EPM task. 
The last but not the least, the 
endocannabinoidergic system may modulate 
serotonergic transmission through two possible 
mechanisms including: 1- By regulating the 
activity of afferents into serotonin-producing 
neurons [26] and 2-By directly modulating the 
functions of a distinct subset of serotonergic 
neurons [27]. Concerning to cannabinoidergic and 
serotonergic systems interactions, some studies 
have suggested that cannabinoids and their 
receptor agonists such as anandamide and 
WIN55212-2, inhibit the uptake of serotonin into 
cortical synaptosomes possibly through reducing 
the activity of the energy source, Na+/K+-ATPase 
[28]. Thus, when a cannabinoid receptor agonist 
is used, it blocks the involved transporters and 
ultimately enhances serotonin level in different 
brain regions [29]. 
In conclusion, our data indicate effects of the 
endocannabinoidergic system that may modulate 
serotonergic transmission depend on several 
factors, such as the nature of the task, neural 
circuit and specific drug used.  
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